Latest News of IMAB
FDA grants breakthrough status to J&J's nipocalimab for SjD treatment
By Yahoo! Finance |
3 weeks ago
The FDA awarded Johnson & Johnson's nipocalimab its second breakthrough therapy designation for treating moderate-to-severe Sjögren's disease. The Phase II DAHLIAS study showed positive outcomes, lea...
Otsuka's sibeprenlimab shows promise in Phase III IgA nephropathy trial
By Yahoo! Finance |
1 month ago
Otsuka Pharmaceutical's Phase III trial on sibeprenlimab for IgA nephropathy showed positive interim results. The monoclonal antibody demonstrated a significant reduction in urine protein levels, meet...
GSK's depemokimab shows promise in Phase III trials for chronic rhinosinusitis
By Yahoo! Finance |
1 month ago
GSK's Phase III trials of depemokimab in CRSwNP patients showed significant improvements compared to placebo, meeting primary endpoints. The drug's potential as a convenient treatment option is promis...
-
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
By Yahoo! Finance | 1 month agoGSK plc announced positive results from phase 3 trials for depemokimab in treating chronic rhinosinusitis with nasal polyps. The trials met primary endpoints, showing efficacy and safety in reducing p...
-
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
By Yahoo! Finance | 2 months agoJohnson & Johnson's TAR-200 plus cetrelimab combination therapy shows promising results in reducing tumor size for patients with muscle-invasive bladder cancer, potentially improving surgical outcomes...
-
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
By Yahoo! Finance | 3 months agoJohnson & Johnson submitted a BLA to the FDA for nipocalimab, a potential treatment for generalized myasthenia gravis. Data from the Vivacity-MG3 study showed sustained disease control in gMG patients...